TY - JOUR
T1 - Erratum
T2 - Mitigation of endemic GI-tract pathogen-mediated inflammation through development of multimodal treatment regimen and its impact on SIV acquisition in rhesus macaques (PLoS Pathogens (2021) 17:5 (e1009565) DOI: 10.1371/journal.ppat.1009565)
AU - Bochart, Rachele M.
AU - Busman-Sahay, Kathleen
AU - Bondoc, Stephen
AU - Morrow, David W.
AU - Ortiz, Alexandra M.
AU - Fennessey, Christine M.
AU - Fischer, Miranda B.
AU - Shiel, Oriene
AU - Swanson, Tonya
AU - Shriver-Munsch, Christine M.
AU - Crank, Hugh B.
AU - Armantrout, Kimberly M.
AU - Barber-Axthelm, Aaron M.
AU - Langner, Charlotte
AU - Moats, Cassandra R.
AU - Labriola, Caralyn S.
AU - MacAllister, Rhonda
AU - Axthelm, Michael K.
AU - Brenchley, Jason M.
AU - Keele, Brandon F.
AU - Estes, Jacob D.
AU - Hansen, Scott G.
AU - Smedley, Jeremy V.
N1 - Publisher Copyright:
© 2023 Bochart et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2023/4
Y1 - 2023/4
N2 - The published article [1] presents data from two separate animal studies. The first study conducted at the National Cancer Institute (NCI) comprised an 18-rhesus macaque (RM) intrarectal dose titration experiment to determine appropriate dosing of SIVmac239X for use in viral transmission/early necropsy studies. This notice addresses errors in the methodological description for the initial NCI study: in these animals, the authors did not assess gastrointestinal pathogens, microbiome, immunology, or mucosal barrier integrity, and the handling and treatment of the animals differed from that employed in the subsequent study conducted at Oregon National Primate Research Center (ONPRC). The originally published Materials and Methods section incorrectly reported some similarities between the animal handling and treatment regimens used in the two studies. This Correction provides amended methodological information, including that the multimodal therapeutic regimen for the NCI study included only metronidazole and fenbendazole, while the regimen for the ONPRC study included enrofloxacin, paromomycin, fenbendazole, and azithromycin.
AB - The published article [1] presents data from two separate animal studies. The first study conducted at the National Cancer Institute (NCI) comprised an 18-rhesus macaque (RM) intrarectal dose titration experiment to determine appropriate dosing of SIVmac239X for use in viral transmission/early necropsy studies. This notice addresses errors in the methodological description for the initial NCI study: in these animals, the authors did not assess gastrointestinal pathogens, microbiome, immunology, or mucosal barrier integrity, and the handling and treatment of the animals differed from that employed in the subsequent study conducted at Oregon National Primate Research Center (ONPRC). The originally published Materials and Methods section incorrectly reported some similarities between the animal handling and treatment regimens used in the two studies. This Correction provides amended methodological information, including that the multimodal therapeutic regimen for the NCI study included only metronidazole and fenbendazole, while the regimen for the ONPRC study included enrofloxacin, paromomycin, fenbendazole, and azithromycin.
UR - http://www.scopus.com/inward/record.url?scp=85153123900&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85153123900&partnerID=8YFLogxK
U2 - 10.1371/journal.ppat.1011343
DO - 10.1371/journal.ppat.1011343
M3 - Comment/debate
C2 - 37075022
AN - SCOPUS:85153123900
SN - 1553-7366
VL - 19
JO - PLoS pathogens
JF - PLoS pathogens
IS - 4
M1 - e1011343
ER -